Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9773 (CytoFab) in severe sepsis and/or septic shock
NCT01145560Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of AZD9773 in sepsis and septic shock (3 arms), sponsored by AstraZeneca. Primary endpoint: Ventilator-free Days at 28 days. Started Oct 2010; status: completed.
02
Drugs
AZD9773
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT01145560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01145560.